<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy	</title>
	<atom:link href="https://www.novumpr.nl/2016/09/14/european-commission-approves-ipsens-cabometyx-cabozantinib-tablets-for-the-treatment-of-advanced-renal-cell-carcinoma-rcc-in-adults-following-prior-vascular-endothelial-growth-fa/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2016/09/14/european-commission-approves-ipsens-cabometyx-cabozantinib-tablets-for-the-treatment-of-advanced-renal-cell-carcinoma-rcc-in-adults-following-prior-vascular-endothelial-growth-fa/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=european-commission-approves-ipsens-cabometyx-cabozantinib-tablets-for-the-treatment-of-advanced-renal-cell-carcinoma-rcc-in-adults-following-prior-vascular-endothelial-growth-fa</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Wed, 14 Sep 2016 07:33:04 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
